Cost-effectiveness of Upadacitinib vs. Tofacitinib for moderate-to-severe rheumatoid arthritis in China
In the context of China's healthcare system, Upadacitinib represents a cost-effective long-term first-line treatment option for moderate-to-severe RA patients.
Authors
- Linyu Geng (ORCID: https://orcid.org/0000-0002-8983-2326)
- Saisai Huang (ORCID: https://orcid.org/0000-0002-7815-4275)
- Xinyi Xu (ORCID: https://orcid.org/0000-0002-3604-7906)
- Xue Xu (ORCID: https://orcid.org/0000-0003-3796-6872)
- Jun Liang
Institutions
- Nanjing Drum Tower Hospital (CN)
Publication Details
- Journal
- Immunotherapy
- Published
- 2024-10-27
- DOI
- https://doi.org/10.1080/1750743x.2024.2426972
- Citations
- 2
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.94
Funders
- Nanjing University